Rodion A Velichinskii, Maria A Streltsova, Julia D Vavilova, Anna A Boyko, Tatyana N Belovezhets, Maria V Grechikhina, Elena I Kovalenko
{"title":"PSCA-CAR-NK细胞对表达psca的肿瘤细胞发挥细胞毒活性,并具有特定的趋化因子特征。","authors":"Rodion A Velichinskii, Maria A Streltsova, Julia D Vavilova, Anna A Boyko, Tatyana N Belovezhets, Maria V Grechikhina, Elena I Kovalenko","doi":"10.1016/j.jcyt.2025.08.001","DOIUrl":null,"url":null,"abstract":"<p><p>Genetic modification of NK cells with chimeric antigen receptors (CARs) is a rapidly evolving approach to treating tumor diseases. CAR-NK technology is being developed for various antigens associated with both hematologic and solid tumors. In this study, peripheral blood NK cells overexpressing CAR against prostate stem cell antigen (PSCA) were obtained using retroviral transduction. To assess the specific functional activity of the PSCA-CAR-NK cells, we used cell lines modified to express surface PSCA via lentiviral transduction. The increased specific cytotoxic responses of PSCA-CAR-NK cells against these PSCA-positive cell lines were demonstrated using two alternative in vitro methods: a degranulation assay measuring CD107a expression level on the NK cell surface and a cytotoxicity test assessing fluorescent dye release from dying target cells. The specific cytotoxicity of PSCA-CAR-NK cells was confirmed using the BxPС-3 tumor cell line spontaneously expressing PSCA. In addition, profiles of chemokine receptors involved in the antitumor response, including CCR7, CXCR1, CXCR3 and CXCR4, were analyzed in NK cell subsets ex vivo, in IL-2/feeder cell-activated NK cells, and in transduced NK cells. We observed that the expression levels of CCR7 and CXCR4 on CD56<sup>+</sup> NK cells and in the CD56<sup>+</sup>CD57<sup>+</sup> fraction were highest in the activated state, decreasing after transduction. Proportion of NK cells expressing the CXCR1 receptor markedly decreased after activation while that of CXCR3 increased, the transduction procedure had no significant influence on the CXCR1 and CXCR3 levels. Following transduction, PSCA-CAR-NK cells showed increased levels of CCR7 expression compared to unmodified GFP-NK cells, most marked in more mature cells expressing CD57 or KIR2DL2/3. Moreover, an increased CXCR3 expression was noted in CD57<sup>+</sup> subsets of the PSCA-CAR-NK cells. Since the ability of NK cells to migrate to lymph nodes and reach tumor sites depends on the presence of CCR7 and CXCR3 receptors, respectively, the patterns we have identified in the distribution of these chemokine receptors on cytotoxic PSCA-CAR-NK cells are particularly interesting and may be useful in the context of fighting solid tumors.</p>","PeriodicalId":50597,"journal":{"name":"Cytotherapy","volume":" ","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"PSCA-CAR-NK cells exert cytotoxic activity against PSCA-expressing tumor cells and are characterized by a specific chemokine profile.\",\"authors\":\"Rodion A Velichinskii, Maria A Streltsova, Julia D Vavilova, Anna A Boyko, Tatyana N Belovezhets, Maria V Grechikhina, Elena I Kovalenko\",\"doi\":\"10.1016/j.jcyt.2025.08.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Genetic modification of NK cells with chimeric antigen receptors (CARs) is a rapidly evolving approach to treating tumor diseases. CAR-NK technology is being developed for various antigens associated with both hematologic and solid tumors. In this study, peripheral blood NK cells overexpressing CAR against prostate stem cell antigen (PSCA) were obtained using retroviral transduction. To assess the specific functional activity of the PSCA-CAR-NK cells, we used cell lines modified to express surface PSCA via lentiviral transduction. The increased specific cytotoxic responses of PSCA-CAR-NK cells against these PSCA-positive cell lines were demonstrated using two alternative in vitro methods: a degranulation assay measuring CD107a expression level on the NK cell surface and a cytotoxicity test assessing fluorescent dye release from dying target cells. The specific cytotoxicity of PSCA-CAR-NK cells was confirmed using the BxPС-3 tumor cell line spontaneously expressing PSCA. In addition, profiles of chemokine receptors involved in the antitumor response, including CCR7, CXCR1, CXCR3 and CXCR4, were analyzed in NK cell subsets ex vivo, in IL-2/feeder cell-activated NK cells, and in transduced NK cells. We observed that the expression levels of CCR7 and CXCR4 on CD56<sup>+</sup> NK cells and in the CD56<sup>+</sup>CD57<sup>+</sup> fraction were highest in the activated state, decreasing after transduction. Proportion of NK cells expressing the CXCR1 receptor markedly decreased after activation while that of CXCR3 increased, the transduction procedure had no significant influence on the CXCR1 and CXCR3 levels. Following transduction, PSCA-CAR-NK cells showed increased levels of CCR7 expression compared to unmodified GFP-NK cells, most marked in more mature cells expressing CD57 or KIR2DL2/3. Moreover, an increased CXCR3 expression was noted in CD57<sup>+</sup> subsets of the PSCA-CAR-NK cells. Since the ability of NK cells to migrate to lymph nodes and reach tumor sites depends on the presence of CCR7 and CXCR3 receptors, respectively, the patterns we have identified in the distribution of these chemokine receptors on cytotoxic PSCA-CAR-NK cells are particularly interesting and may be useful in the context of fighting solid tumors.</p>\",\"PeriodicalId\":50597,\"journal\":{\"name\":\"Cytotherapy\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2025-08-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cytotherapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.jcyt.2025.08.001\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cytotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jcyt.2025.08.001","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
利用嵌合抗原受体(CARs)对NK细胞进行遗传修饰是一种快速发展的治疗肿瘤疾病的方法。CAR-NK技术正在开发用于与血液学和实体肿瘤相关的各种抗原。在这项研究中,通过逆转录病毒转导获得了过表达CAR对抗前列腺干细胞抗原(PSCA)的外周血NK细胞。为了评估PSCA- car - nk细胞的特异性功能活性,我们使用经过修饰的细胞系,通过慢病毒转导表达表面PSCA。PSCA-CAR-NK细胞对这些psca阳性细胞系的特异性细胞毒性反应增加,使用两种不同的体外方法进行了验证:一种是测量NK细胞表面CD107a表达水平的脱颗粒试验,另一种是评估垂死靶细胞荧光染料释放的细胞毒性试验。利用自发表达PSCA的BxPС-3肿瘤细胞系证实了PSCA- car - nk细胞的特异性细胞毒性。此外,我们还分析了NK细胞亚群、IL-2/饲养细胞激活的NK细胞和转导NK细胞中参与抗肿瘤反应的趋化因子受体(包括CCR7、CXCR1、CXCR3和CXCR4)的谱。我们观察到CCR7和CXCR4在CD56+ NK细胞和CD56+CD57+部分的表达水平在激活状态下最高,转导后下降。激活后表达CXCR1受体的NK细胞比例明显下降,而表达CXCR3受体的NK细胞比例上升,转导过程对CXCR1和CXCR3水平无显著影响。转导后,与未修饰的GFP-NK细胞相比,pca - car - nk细胞的CCR7表达水平升高,在表达CD57或KIR2DL2/3的更成熟的细胞中最明显。此外,在PSCA-CAR-NK细胞的CD57+亚群中发现CXCR3表达增加。由于NK细胞迁移到淋巴结和到达肿瘤部位的能力分别取决于CCR7和CXCR3受体的存在,因此我们已经确定的这些趋化因子受体在细胞毒性PSCA-CAR-NK细胞上的分布模式特别有趣,并且可能在对抗实体肿瘤的背景下有用。
PSCA-CAR-NK cells exert cytotoxic activity against PSCA-expressing tumor cells and are characterized by a specific chemokine profile.
Genetic modification of NK cells with chimeric antigen receptors (CARs) is a rapidly evolving approach to treating tumor diseases. CAR-NK technology is being developed for various antigens associated with both hematologic and solid tumors. In this study, peripheral blood NK cells overexpressing CAR against prostate stem cell antigen (PSCA) were obtained using retroviral transduction. To assess the specific functional activity of the PSCA-CAR-NK cells, we used cell lines modified to express surface PSCA via lentiviral transduction. The increased specific cytotoxic responses of PSCA-CAR-NK cells against these PSCA-positive cell lines were demonstrated using two alternative in vitro methods: a degranulation assay measuring CD107a expression level on the NK cell surface and a cytotoxicity test assessing fluorescent dye release from dying target cells. The specific cytotoxicity of PSCA-CAR-NK cells was confirmed using the BxPС-3 tumor cell line spontaneously expressing PSCA. In addition, profiles of chemokine receptors involved in the antitumor response, including CCR7, CXCR1, CXCR3 and CXCR4, were analyzed in NK cell subsets ex vivo, in IL-2/feeder cell-activated NK cells, and in transduced NK cells. We observed that the expression levels of CCR7 and CXCR4 on CD56+ NK cells and in the CD56+CD57+ fraction were highest in the activated state, decreasing after transduction. Proportion of NK cells expressing the CXCR1 receptor markedly decreased after activation while that of CXCR3 increased, the transduction procedure had no significant influence on the CXCR1 and CXCR3 levels. Following transduction, PSCA-CAR-NK cells showed increased levels of CCR7 expression compared to unmodified GFP-NK cells, most marked in more mature cells expressing CD57 or KIR2DL2/3. Moreover, an increased CXCR3 expression was noted in CD57+ subsets of the PSCA-CAR-NK cells. Since the ability of NK cells to migrate to lymph nodes and reach tumor sites depends on the presence of CCR7 and CXCR3 receptors, respectively, the patterns we have identified in the distribution of these chemokine receptors on cytotoxic PSCA-CAR-NK cells are particularly interesting and may be useful in the context of fighting solid tumors.
期刊介绍:
The journal brings readers the latest developments in the fast moving field of cellular therapy in man. This includes cell therapy for cancer, immune disorders, inherited diseases, tissue repair and regenerative medicine. The journal covers the science, translational development and treatment with variety of cell types including hematopoietic stem cells, immune cells (dendritic cells, NK, cells, T cells, antigen presenting cells) mesenchymal stromal cells, adipose cells, nerve, muscle, vascular and endothelial cells, and induced pluripotential stem cells. We also welcome manuscripts on subcellular derivatives such as exosomes. A specific focus is on translational research that brings cell therapy to the clinic. Cytotherapy publishes original papers, reviews, position papers editorials, commentaries and letters to the editor. We welcome "Protocols in Cytotherapy" bringing standard operating procedure for production specific cell types for clinical use within the reach of the readership.